SEC Form D private-offering filing
KALA BIO, Inc.
A new SEC Form D private-offering notice from Arlington, MA, a $1,753,500 filer-stated offering target in Biotech. The source filing is one click away.
Clinical stage biopharmaceutical company developing therapies for rare and severe eye diseases, formerly Kala Pharmaceuticals, publicly traded on Nasdaq as KALA.
Filed 2026-03-17Filed to raise $1,753,500First money in 2026-03-03Raised so far $1,753,500HQ (as filed) Arlington, MASector Biotech ✓Stage (inferred) SeedCall status Needs classification
Source linked the Form D on EDGAR↗Website verified kalarx.com↗Named in the filing 5 executives & directors
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.